Prof. Dr. Stephan Weidinger
Prof. Dr. Stephan Weidinger
Effects of abrocitinib treatment of atopic dermatitis on skin barrier function.
Atopic Dermatitis
No Intervention
Open-label, non-randomized, single-arm, 12-weeks observational clinical and translational study}}
Study Type : | Observational |
Estimated Enrollment : | 20 participants |
Official Title : | Effects of Abrocitinib Treatment of Moderate to Severe Atopic Dermatitis on Skin Barrier Function |
Actual Study Start Date : | September 1, 2022 |
Estimated Primary Completion Date : | December 31, 2023 |
Estimated Study Completion Date : | December 31, 2024 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 18 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Recruiting
UKSH, Campus Kiel
Like, Schleswig-Holstein, Germany, 24105